The number of women having an induction of labour is increasing and is currently used in 33%
of pregnancies for a range of medical reasons. The majority of women are admitted to hospital
to have their labour induced, using methods which are protracted and associated with a poor
birth experience, making them both costly and unpopular. Further, current methods of
outpatient induction are unsuitable, unsafe and/or have a poor acceptability. The COVID-19
pandemic has driven a reduction in the number of face-to-face interactions taking place
across all areas of medicine. Proving the efficacy and safety of Mifepristone would
significantly reduce pre-labour admission rates and hospital length of stay for pregnant
women, who are at particularly higher risk of COVID-19, and reduce delivery costs.